Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.

Georgios VlasakakisAntonella NapolitanoRuth BarnardKim BrownJonathan BullmanDavid InmanBart KeymeulenDavid LanhamQuentin LeirensAlexander MacDonaldEnrica MezzalanaKevin PageMinesh PatelCaroline O SavageStefano ZamunerAndre van Maurik

Published in: British journal of clinical pharmacology (2019)

Data from this study revealed maximum target engagement and CD3ɛ/TCR modulation is achieved at doses of 18, 27 mg of otelixizumab. These findings can be useful in guiding dose selection in clinical trials with anti-CD3ɛ mAbs.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
social media
chronic kidney disease
cardiovascular disease
type diabetes
metabolic syndrome
big data
patient reported outcomes